Juanxia Meng

Tianjin First Center Hospital — China

Medicine · Health Sciences

12h-index770citations39works3.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(15), Hematopoietic Stem Cell Transplantation(5), Hemoglobinopathies and Related Disorders(5), Virus-based gene therapy research(5), Mesenchymal stem cell research(4)

Publications39 total

Early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies
Frontiers in Immunology·2025Open Access
This is a title in sentence case:early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies
Blood·2025
Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation
Frontiers in Immunology·2025· 3 citedOpen Access
Anti-FcRL5 CAR-T exhibits anti-MM activity against EMM after progression of anti-BCMA and anti-GPRC5D CAR-T: a case report
Blood Advances·2024· 3 citedOpen Access
Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia
Chinese Medical Journal·2024Open Access
Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation
Leukemia·2024· 9 citedOpen Access
Multi-centers experience using therapeutic plasma exchange for corticosteroid/tocilizumab-refractory cytokine release syndrome following CAR-T therapy
International Immunopharmacology·2024· 10 cited
Prophylactic or Preemptive Donor-Derived CD19 CAR-T Cell Infusion for Preventing Relapse in High-Risk B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation
Blood·2023
A Phase I Clinical Trial of CLL-1 CAR-T Cells for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia in Adults
Blood·2023· 21 cited
Low-dose administration of prednisone has a good effect on the treatment of prolonged hematologic toxicity post-CD19 CAR-T cell therapy
Frontiers in Immunology·2023· 9 citedOpen Access
Prophylactic or Preemptive Infusion Of Donor-Derived CD19 CAR-T Cell Therapy in High-Risk B-Cell Acute Lymphoblastic Leukaemia Following Allogeneic Transplantation: A Post-Hoc Analysis of Two Clinical Trials
SSRN Electronic Journal·2023Open Access
Successful treatment of second-time CAR-T 19 therapy after failure of first-time CAR-T 19 and ibrutinib therapy in relapsed mantle cell lymphoma
Advances in Clinical and Experimental Medicine·2022· 3 citedOpen Access
A Prospective Trial Comparing Haploidentical Donor Transplantation With Cord Blood Versus HLA-Matched Sibling Donor Transplantation for Hematologic Malignancy Patients
Cell Transplantation·2022· 2 citedOpen Access
[Effect and Involved Mechanism of RSL3-induced Ferroptosis in Acute Leukemia Cells MOLM13 and Drug-resistant Cell Lines].
Zhongguo shiyan xueyexue zazhi·2021· 2 cited
CD19 CAR-T cell treatment conferred sustained remission in B-ALL patients with minimal residual disease
Cancer Immunology Immunotherapy·2021· 21 citedOpen Access
Efficacy and safety of humanized anti‐CD19‐CAR‐T therapy following intensive lymphodepleting chemotherapy for refractory/relapsed B acute lymphoblastic leukaemia
British Journal of Haematology·2020· 50 citedOpen Access
[Analysis on poor efficacy factors in the treatment of recurrent/refractory B-cell lymphoma with CD19 CAR-T cells].
PubMed·2020· 1 cited
HLA-matched and HLA-haploidentical allogeneic CD19-directed chimeric antigen receptor T-cell infusions are feasible in relapsed or refractory B-cell acute lymphoblastic leukemia before hematopoietic stem cell transplantation
Leukemia·2019· 20 citedOpen Access
Plasma Exchange Can Be an Alternative Therapeutic Modality for Severe Cytokine Release Syndrome after Chimeric Antigen Receptor-T Cell Infusion: A Case Report
Clinical Cancer Research·2018· 53 cited
Iron overload impairs normal hematopoietic stem and progenitor cells through reactive oxygen species and shortens survival in myelodysplastic syndrome mice
Haematologica·2018· 67 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Mingfeng Zhao(34), Wenyi Lu(22), Xia Xiao(22), Xiao Chai(13), Juan Mu(12), Qing Li(11), Xiaoyuan He(11), Haibo Zhu(11), Hairong Lyu(10), Xin Jin(9), Yedi Pu(9), Deguan Li(7), Aimin Meng(7), Xiaoli Cao(6), Qi Deng(6), Yanyu Jiang(6), Meng Zhang(6), Yanyu Jiang(5), Rui Sun(5), Jiaxi Wang(5)